Enter assignee name

EPO Patents = 1

Forward Citations = 61

Loading Chart...

3 inventors (with patents filed for the assignee):

Francis Lee (13 out of 13 patents)

Jonathan D Steckbeck (13 out of 13 patents)

Hannes Holste (13 out of 13 patents)

13 patents: Sort by Forward Citations

1. 12614613 - Generating enhanced graphical user interfaces for presentation of anti-infective design spaces for selecting drug candidates (2026-04-28),

2. 12462902 - Artificial intelligence engine architecture for generating candidate drugs (2025-11-04),

3. 12087404 - Generating anti-infective design spaces for selecting drug candidates (2024-09-10),

4. 12006541 - Methods and apparatuses for generating peptides by synthesizing a portion of a design space to identify peptides having non-canonical amino acids (2024-06-11),

5. 11967400 - Generating enhanced graphical user interfaces for presentation of anti-infective design spaces for selecting drug candidates (2024-04-23),

6. 11848076 - Generating enhanced graphical user interfaces for presentation of anti-infective design spaces for selecting drug candidates (2023-12-19),

7. 11587643 - Methods and apparatuses for a unified artificial intelligence platform to synthesize diverse sets of peptides and peptidomimetics (2023-02-21),

8. 11512345 - Methods and apparatuses for generating peptides by synthesizing a portion of a design space to identify peptides having non-canonical amino acids (2022-11-29),

9. 11462304 - Artificial intelligence engine architecture for generating candidate drugs (2022-10-04),

10. 11436246 - Generating enhanced graphical user interfaces for presentation of anti-infective design spaces for selecting drug candidates (2022-09-06),

11. 11424008 - Generating anti-infective design spaces for selecting drug candidates (2022-08-23),

12. 11403316 - Generating enhanced graphical user interfaces for presentation of anti-infective design spaces for selecting drug candidates (2022-08-02),

13. 11049590 - Artificial intelligence engine architecture for generating candidate drugs (2021-06-29),

Peptilogics, Inc. is a biotechnology company that specializes in developing novel peptide therapeutics to combat antibiotic-resistant bacterial infections. Their proprietary platform combines AI-driven computational design with synthetic biology to create innovative solutions for healthcare. Peptilogics is dedicated to addressing the growing threat of drug-resistant bacteria and improving patient outcomes worldwide.

Profile summary based on public USPTO records.